Association between JAK2 V617F variable allele frequency and risk of thrombotic events in patients with myeloproliferative neoplasms.

Autor: Brown R; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., Jasiakiewicz J; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., Greer V; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., Hindley A; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., McDowell K; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., Devlin E; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., Clarke K; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., Buckley F; Haematology Department, NHS Highland, Inverness, Scotland, UK., Crean C; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., McGimpsey J; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., Cuthbert RJG; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., Cunningham N; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., Arnold C; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., Finnegan D; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., Benson G; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK., McMullin MF; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK. M.McMullin@qub.ac.uk.; Centre for Medical Education (CME), Queen's University Belfast, Belfast, Northern Ireland, UK. M.McMullin@qub.ac.uk., Catherwood MA; Haematology, Belfast City Hospital, BHSCT, Belfast, Northern Ireland, UK.
Jazyk: angličtina
Zdroj: Irish journal of medical science [Ir J Med Sci] 2024 Dec; Vol. 193 (6), pp. 2883-2888. Date of Electronic Publication: 2024 Aug 14.
DOI: 10.1007/s11845-024-03776-5
Abstrakt: Background: Myeloproliferative neoplasms (MPNs) are a group of chronic disorders of the bone marrow characterised by the overproduction of clonal myeloid stem cells. The most common driver mutation found in MPNs is a point mutation on exon 14 of the JAK2 gene, JAK2 V617F . Various studies have suggested that measuring the variable allele frequency (VAF) of JAK2 V617F may provide useful insight regarding diagnosis, treatment, risks and outcomes in MPN patients. In particular, JAK2 V617F has been associated with increased risk of thrombotic events, a leading cause of mortality in MPNs.
Aims: The aim of this study was to determine if JAK2 V617F VAF was associated with clinical outcomes in patients with MPN.
Methods: JAK2 V617F VAF was determined by quantitative PCR (qPCR) in a cohort of 159 newly diagnosed MPN patients, and the association of JAK2 V617F VAF and risk of thrombosis was examined in this cohort.
Results: We observed a significantly higher JAK2 V617F VAF in PV and PMF versus ET. A significant association was observed between JAK2 V617F VAF and risk of thrombotic events. When patients were stratified by thrombotic events prior to and post diagnosis, an association with JAK2 V617F VAF was only observed with post diagnosis thrombotic events. Of note, these associations were not observed when looking at each MPN subtype in isolation.
Conclusions: We have shown that a higher JAK2 V617F VAF is associated with thrombotic events post MPN diagnosis. JAK2 V617F VAF may therefore provide a valuable prognostic indicator for risk of thrombosis in MPNs.
Competing Interests: Declarations. Patient Consent: Not required. Provence and Peer review: Not commissioned; externally peer reviewed. Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: